

Cover Story
Free
With a simplified tech transfer agreement, six industry partners and 15 compounds (but no dedicated research funds), NCI challenges investigators to think creatively.
In Brief


Drugs & Targets


Trending Stories
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE
“Deidentified” ≠ “deidentifiable” - After a year, Stephenson institute sees a broader role in funding pancreatic cancer research, fostering collaborations
“We are not just funding research. We are building a trusted community.” - Lou Weiner to step down as director of Georgetown’s Lombardi CCC after 18 years
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
- Trump administration announces “major crackdown” on healthcare fraud











